DH 4243
Alternative Names: DH-4243; Tranexamic acid - DaiichiLatest Information Update: 14 Oct 2021
At a glance
- Originator Daiichi Sankyo Company
- Class Amines; Anti-infectives; Anti-inflammatories; Antifibrinolytics; Antihaemorrhagics; Cardiovascular therapies; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Plasmin inhibitors; Plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Melanosis; Skin disorders
Most Recent Events
- 12 May 2008 Discontinued - Clinical-Phase-Unknown for Melanosis in Japan (PO)
- 12 May 2008 Discontinued - Clinical-Phase-Unknown for Skin disorders in Japan (PO)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc